Dr. Nicola Mason | Immunotherapy Innovations | Veterinary Cancer Pioneers Podcast Ep.19
Why your dog's cancer treatment may shape what's available for humans in five years
Dr. Nicola Mason with Dr. Rachel Venable
Episode aired Oct 6, 2024·Page synthesised Jun 7, 2026·Last reviewed Jun 7, 2026
What this episode covers
- Pet dogs that develop cancer naturally give researchers a better model for new treatments than lab mice.
- Therapies like CAR T-cell and mRNA antibodies are being studied in dogs and humans together.
- The same research may help both species.
Why it matters
When dogs and humans share cancer biology, immune patterns, and treatment responses, progress for one may speed up progress for the other. This affects treatment access, cost, immune therapy options, and future cancer outcomes for both species.
What stands out
- Lab mouse models frequently fail to predict how cancer treatments will work in humans, which is one reason the Cancer Moonshot includes a canine immunotherapy network (comparative oncology research framing)
- Pet dogs share more immune system similarities with humans than rodent models do, making them a more realistic cancer treatment test (NIH Cancer Moonshot Canine Immunotherapy Network framing)
- Researchers hope that off-the-shelf cell therapies derived from healthy donors may substantially reduce treatment costs compared with personalized approaches like CAR T-cell therapy (current research pipeline framing)
Best-supported action
The single highest-leverage move from this episode, anchored in the strongest evidence the speaker presents.
Ask your veterinary oncologist which treatment options for your dog's cancer are considered standard care today, and which are still experimental or research-stage.
Where to start
Small low-friction starters covering the main moves from this episode.
- Notice whether your veterinary oncologist mentions clinical trial options during the diagnosis conversation
- Ask about veterinary teaching hospital affiliations if your case is uncommon or hard to treat
- If appropriate, ask whether your dog's case could contribute to research that may help future dogs and people
Other supported actions
Further actions discussed in this episode, ordered from strongest to weakest evidence. This is one expert's view, the full topic compares and ranks across experts.
- At the diagnosis visit, write down three things: your dog's specific cancer type, the standard treatment options available today, and which options (if any) are still research-stage or experimental.Limited evidence
- If your dog's cancer is uncommon or aggressive, ask your vet whether referral to a teaching hospital affiliated with the Cancer Moonshot network would change options.Limited evidence
- If clinical trial participation is offered, ask specifically about cost coverage, time commitment, and what happens if your dog leaves the trial.Limited evidence
Full context, impact ratings, and timing — available in related topics
Questions to take to your doctor
- Which treatment options for my dog's cancer are considered standard care today, and which are still experimental or research-stage?
- Given my dog's diagnosis, would referral to a university veterinary teaching hospital open clinical trial options that could help us both?
- Given the cost gap between standard and advanced cancer treatment, would my dog's case potentially qualify for any current research-supported protocols?
Full doctor prep with ranked questions available in the full topic page
Context
Helps explain why pet cancer research benefits both species (spontaneous canine tumors are a more realistic model than lab mice for human cancer), and what immunotherapy approaches (CAR T-cell, mRNA antibodies) may become available for both pets and humans in coming years. Strongest on translational research and immunotherapy pipeline. Mainstream-anchored, mainly published at the academic research frontier. Commercial layer: episode produced by ImpriMed (precision diagnostics sponsor); her own research funding is academic + NIH.
This is based on a leading researcher's view of the field, not on a settled treatment guideline. Many of the therapies discussed (CAR T-cell, mRNA antibodies) are research-stage and not widely available yet. The episode is sponsored by a precision diagnostics company, which is worth knowing. This does not mean you should change or stop your dog's current cancer treatment on your own.
Where people go wrong
- Assuming research-stage immunotherapy is available as a standard treatment todayYou may delay decisions waiting for unavailable options, while real choices about current care need to be made
- Dismissing your dog's case as not relevant to research without askingMany cancer types are being actively studied; opportunities for participation may exist that your primary vet does not routinely mention
What to expect over time
- First 2 weeks after diagnosisAsk about clinical trials and teaching hospital options; document what is available now vs research-stage
- Treatment decision (weeks 2-6)If trial participation is available and fits, evaluate logistics; otherwise plan with current standard care
- Long-term trackingStay engaged with your vet; immunotherapy options may evolve over the course of your dog's treatment